Frequent topoisomerase IV mutations associated with fluoroquinolone resistance in Ureaplasma species

被引:18
|
作者
Song, Jingjuan [1 ]
Qiao, Yingli [1 ]
Kong, Yingying [2 ]
Ruan, Zhi [2 ]
Huang, Jun [1 ]
Song, Tiejun [1 ]
Zhang, Jun [1 ]
Xie, Xinyou [1 ]
机构
[1] Zhejiang Univ, Clin Lab, Sir Run Run Shaw Hosp, Coll Med, Hangzhou 310016, Zhejiang, Peoples R China
[2] Zhejiang Univ, Biomed Res Ctr, Sir Run Run Shaw Hosp, Coll Med, Hangzhou 310016, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
IN-VITRO ACTIVITY; MYCOPLASMA-HOMINIS; MYCOBACTERIUM-TUBERCULOSIS; PRETERM INFANTS; UREALYTICUM; PARVUM; GYRA; SUSCEPTIBILITY; IDENTIFICATION; PREVALENCE;
D O I
10.1099/jmm.0.000153
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
This study aimed to investigate the role of quinolone resistance-determining regions (ORDRs) of DNA gyrase (encoded by gyrA and gyrB) and topoisomerase IV (encoded by parC and parE) associated with fluoroquinolone resistance. A total of 114 Ureaplasma spp. strains, isolated from clinical female patients with symptomatic infection, were tested for species distribution and susceptibility to four fluoroquinolones. Moreover, we analysed the QRDRs and compared these with 14 ATCC reference strains of Ureaplasma spp. serovars to identify mutations that caused antimicrobial resistance. Our study indicated that moxifloxacin was the most effective fluoroquinolone against Ureaplasma spp. (MIC range: 0.125-32 mu g ml(-1)). However, extremely high MICs were estimated for ciprofloxacin (MIC range: 1-256 mu g ml(-1)) and ofloxacin (MIC range: 0.5-128 mu g ml(-1)), followed by levofloxacin (MIC range: 0.5-64 mu g ml(-1)). Seven amino acid substitutions were discovered in GyrB, ParC and ParE, but not in GyrA. Ser-83 -> Leu/Trp (C248T/G) in ParC and Arg-448 -> Lys (G1343A) in ParE, which were potentially responsible for fluoroquinolone resistance, were observed in 89 (77.2%) and three (2.6%) strains, respectively. Pro-462 -> Ser (C13841), Asn-481 -> Ser (A1442G) and Ala-493 -> Val (014781) in GyrB and Met-105 -> Ile (G315T) in ParC seemed to be neutral polymorphisms, and were observed and occurred along with the amino acid change of Ser-83 -> Leu (C2481) in ParC. Interestingly, two novel mutations of ParC and ParE were independently found in four strains. These observations suggest that amino acid mutation in topoisomerase IV appears to be the leading cause of fluoroquinolone resistance, especially the mutation of Ser-83 -> Leu (02481) in ParC. Moxifloxacin had the best activity against strains with Ser-83 -> Leu mutation.
引用
收藏
页码:1315 / 1320
页数:6
相关论文
共 50 条
  • [1] DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis
    Weigel, LM
    Anderson, GJ
    Tenover, FC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) : 2582 - 2587
  • [2] Chromosomal Mutations Responsible for Fluoroquinolone Resistance in Ureaplasma Species in the United States
    Xiao, Li
    Crabb, Donna M.
    Duffy, Lynn B.
    Paralanov, Vanya
    Glass, John I.
    Waites, Ken B.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (05) : 2780 - 2783
  • [3] Topoisomerase mutations and efflux are associated with fluoroquinolone resistance in Enterococcus faecalis
    Oyamada, Yoshihiro
    Ito, Hideaki
    Inoue, Matsuhisa
    Yamagishi, Jun-ichi
    JOURNAL OF MEDICAL MICROBIOLOGY, 2006, 55 (10) : 1395 - 1401
  • [4] Biochanin A partially restores the activity of ofloxacin and ciprofloxacin against topoisomerase IV mutation-associated fluoroquinolone-resistant Ureaplasma species
    Jin, Hong
    Qi, Chao
    Zou, Yanping
    Kong, Yingying
    Ruan, Zhi
    Ding, Honghui
    Xie, Xinyou
    Zhang, Jun
    JOURNAL OF MEDICAL MICROBIOLOGY, 2017, 66 (11) : 1545 - 1553
  • [5] Fluoroquinolone resistance in Campylobacter species from man and animals:: detection of mutations in topoisomerase genes
    Piddock, LJV
    Ricci, V
    Pumbwe, L
    Everett, MJ
    Griggs, DJ
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) : 19 - 26
  • [6] gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae
    Weigel, LM
    Steward, CD
    Tenover, FC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) : 2661 - 2667
  • [7] Analysis of mutations in DNA gyrase and topoisomerase IV of Ureaplasma urealyticum and Ureaplasma parvum serovars resistant to fluoroquinolones
    Piccinelli, Giorgio
    Gargiulo, Franco
    Biscaro, Valeria
    Caccuri, Francesca
    Caruso, Arnaldo
    De Francesco, Maria Antonia
    INFECTION GENETICS AND EVOLUTION, 2017, 47 : 64 - 67
  • [8] Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance
    Bast, DJ
    Athamna, A
    Duncan, CL
    de Azavedo, JCS
    Low, DE
    Rahav, G
    Farrell, D
    Rubinstein, E
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (01) : 90 - 94
  • [9] Mutations in gyrase and topoisomerase genes associated with fluoroquinolone resistance in Salmonella serovars from retail meats
    Yang, Baowei
    Xi, Meili
    Cui, Shenghui
    Zhang, Xiuli
    Shen, Jinling
    Sheng, Min
    Qu, Dong
    Wang, Xin
    Meng, Jianghong
    FOOD RESEARCH INTERNATIONAL, 2012, 45 (02) : 935 - 939
  • [10] Role of DNA gyrase and topoisomerase IV mutations in fluoroquinolone resistance of Capnocytophaga spp. clinical isolates and laboratory mutants
    Ehrmann, Elodie
    Jolivet-Gougeon, Anne
    Bonnaure-Mallet, Martine
    Fosse, Thierry
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (08) : 2208 - 2212